Mucormycosis following COVID-19: clinical case and literature review.

Khostelidi, S. N.; Zaytsev, V. A.; Pelikh, E. V.; Yashina, E. V.; Rodionova, O. N.; Bogomolova, T. S.; Avdeenko, Y. L.; Klimko, N. N.

Khostelidi, S. N.; Zaytsev, V. A.; Pelikh, E. V.; Yashina, E. V.; Rodionova, O. N.; Bogomolova, T. S.; Avdeenko, Y. L.; Klimko, N. N..

Kliniceskaa Mikrobiologia i Antimikrobnaa Himioterapia ; 23(3):255-262, 2021.

Article in Russian | EMBASE | ID: covidwho-2297801

ABSTRACT

ABSTRACT

Mucormycosis is one of the most aggressive invasive mycoses. The mortality rate of patients with mucormycosis, depending on clinical form and background disease, varies from 30% to 100%. This article provides the first description of mucormycosis in Russia after infection caused by SARS-CoV-2, as well as a review of literature reports on mucormycosis in patients with COVID-19 (as of September 2021).Copyright © 2021, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy. All rights reserved.

Keywords

covid-19; Invasive fungal infection; Mucormycosis; Rhino-orbital mucormycosis; Rhizopus spp; SARS-CoV-2; Zygomycosis; article; coronavirus disease 2019; human; infection complication; mortality rate; mucormycosis/co [Complication]; mucormycosis/di [Diagnosis]; nonhuman; Russian Federation; Severe acute respiratory syndrome coronavirus 2

Fulltext

XML

Search on Google

Full text: Available Collection: Databases of international organizations Database: EMBASE Type of study: Prognostic study / Reviews Language: Russian Journal: Kliniceskaa Mikrobiologia i Antimikrobnaa Himioterapia Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google